{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:39:58Z","timestamp":1793039998870,"version":"4.5.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.canlet.2022.215937","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T11:10:50Z","timestamp":1664881850000},"page":"215937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead"],"prefix":"10.1016","volume":"550","author":[{"given":"Shu-Jin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2022.215937_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2022.215937_bib2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.canlet.2022.215937_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2022.215937_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2022.215937_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2022.215937_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2022.215937_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib10","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib11","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.canlet.2022.215937_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.215937_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","article-title":"The influence of complicating diseases upon leukaemia","volume":"127","author":"Dock","year":"1904","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.canlet.2022.215937_bib15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2022.215937_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib18","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noz175.014","article-title":"Results of phase II clinical trial of oncolytic herpes virus G47\u0394 in patients with glioblastoma","volume":"21","author":"Todo","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3390\/biomedicines9040419","article-title":"Oncolytic virotherapy for cancer: clinical experience","volume":"9","author":"Chaurasiya","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2022.215937_bib21","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.3390\/cancers12123514","article-title":"HSV-1 oncolytic viruses from bench to bedside: an overview of current clinical trials","volume":"12","author":"Koch","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2022.215937_bib22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s11262-017-1488-1","article-title":"Oncolytic viruses: adenoviruses","volume":"53","author":"Niemann","year":"2017","journal-title":"Virus Gene."},{"key":"10.1016\/j.canlet.2022.215937_bib23","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2019.01182","article-title":"Oncolytic adenovirus-A nova for gene-targeted oncolytic viral therapy in HCC","volume":"9","author":"Abudoureyimu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/0042-6822(90)90294-2","article-title":"The complete DNA sequence of vaccinia virus","volume":"179","author":"Goebel","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2022.215937_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.canlet.2022.215937_bib26","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1091\/mbc.12.7.2031","article-title":"Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei","volume":"12","author":"Tolonen","year":"2001","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2022.215937_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3181\/00379727-90-21945","article-title":"Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo","volume":"90","author":"Flanagan","year":"1955","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an antineoplastic agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2022.215937_bib29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM196409242711302","article-title":"Observations on the repeated administration of viruses to a patient with acute leukemia \u2014 a preliminary report","volume":"271","author":"Wheelock","year":"1964","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib30","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.3390\/cancers12123552","article-title":"Newcastle disease virus at the forefront of cancer immunotherapy","volume":"12","author":"Burman","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2022.215937_bib31","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-06-1817","article-title":"An optimized clinical regimen for the oncolytic virus PV701","volume":"13","author":"Hotte","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib33","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.281.17.1588-a","article-title":"Use of Newcastle disease virus vaccine (MTH-68\/H) in a patient with high-grade glioblastoma","volume":"281","author":"Csatary","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2022.215937_bib34","first-page":"635","article-title":"Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68\/H)","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib35","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-020-02495-x","article-title":"Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro","volume":"69","author":"Burke","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2022.215937_bib36","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1073\/pnas.97.12.6803","article-title":"Intergeneric poliovirus recombinants for the treatment of malignant glioma","volume":"97","author":"Gromeier","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2022.215937_bib37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002203","article-title":"Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma","volume":"9","author":"Beasley","year":"2021","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.canlet.2022.215937_bib39","series-title":"Polio-Rhinovirus Conjugate Receives Breakthrough Therapy Designation for Glioblastoma","author":"Levitan","year":"2016"},{"key":"10.1016\/j.canlet.2022.215937_bib40","series-title":"FDA Grants Orphan Drug Designation to PVSRIPO for Advanced Melanoma","author":"Rosa","year":"2021"},{"key":"10.1016\/j.canlet.2022.215937_bib41","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2022.215937_bib42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/v11060562","article-title":"H-1 parvovirus as a cancer-killing agent: past, present, and future","volume":"11","author":"Bretscher","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.canlet.2022.215937_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3172","article-title":"Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy","volume":"38","author":"Leibovich","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib44","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib45","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT139","article-title":"Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: updated results from the phase 1b CAPRA study","volume":"81","author":"Silk","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2022.215937_bib47","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2022.215937_bib48","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-18-2311","article-title":"Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy","volume":"25","author":"Passaro","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib49","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1158\/1078-0432.CCR-14-2009","article-title":"Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy","volume":"21","author":"Rojas","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ebiom.2016.01.022","article-title":"CD8(+) T-cell immune evasion enables oncolytic virus immunotherapy","volume":"5","author":"Pourchet","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2022.215937_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.omto.2021.05.004","article-title":"Oncolytic herpes virus G47\u0394 works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation","volume":"22","author":"Sugawara","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2022.215937_bib52","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/0008-5472.CAN-16-2165","article-title":"Immune checkpoint blockade, immunogenic chemotherapy or IFN-\u03b1 blockade boost the local and abscopal effects of oncolytic virotherapy","volume":"77","author":"Fend","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib53","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ijc.29202","article-title":"Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death","volume":"136","author":"Koks","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2022.215937_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/gt.2011.205","article-title":"Measles virus causes immunogenic cell death in human melanoma","volume":"20","author":"Donnelly","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4220","article-title":"Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs","volume":"9","author":"Brown","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/hum.2014.069","article-title":"Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus","volume":"26","author":"Hirvinen","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib57","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ijc.29048","article-title":"Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma","volume":"136","author":"Siurala","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2022.215937_bib58","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mt.2013.51","article-title":"Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients","volume":"21","author":"Liikanen","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib59","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","article-title":"Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus","volume":"72","author":"Diaconu","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib60","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib61","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.4049\/jimmunol.174.12.7506","article-title":"Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products","volume":"174","author":"Dumitriu","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2022.215937_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","article-title":"Calreticulin and cancer","volume":"31","author":"Fucikova","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2022.215937_bib63","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nature08296","article-title":"Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance","volume":"461","author":"Elliott","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215937_bib64","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/mt.2009.111","article-title":"Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity","volume":"17","author":"Lapteva","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib65","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ccell.2020.12.022","article-title":"Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective","volume":"39","author":"Ramelyte","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.215937_bib67","first-page":"348","article-title":"Systemic reovirus therapy of metastatic cancer in immune-competent mice","volume":"63","author":"Hirasawa","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib68","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2022.215937_bib69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2022.215937_bib70","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/gt.2015.41","article-title":"Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity","volume":"22","author":"Rodr\u00edguez-Garc\u00eda","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib71","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/mt.2008.141","article-title":"The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens","volume":"16","author":"Schirmbeck","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib72","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.virol.2012.11.014","article-title":"Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling","volume":"436","author":"Moerdyk-Schauwecker","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2022.215937_bib74","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.omto.2020.08.004","article-title":"Design of an interferon-resistant oncolytic HSV-1 incorporating redundant safety modalities for improved tolerability","volume":"18","author":"Kennedy","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2022.215937_bib75","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/jcb.25917","article-title":"Interferon-mediated tumor resistance to oncolytic virotherapy","volume":"118","author":"Ebrahimi","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2022.215937_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9101166","article-title":"Resistance mechanisms influencing oncolytic virotherapy, a systematic analysis","volume":"9","author":"Bhatt","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.canlet.2022.215937_bib77","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib78","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/2326-6066.CIR-20-0609","article-title":"ONCR-177, an oncolytic HSV-1 designed to potently activate systemic antitumor immunity","volume":"9","author":"Haines","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2022.215937_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2022.215937_bib81","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccell.2016.05.012","article-title":"Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy","volume":"30","author":"Hou","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.215937_bib82","series-title":"Oncolytic Adenoviruses Synergistically Enhance Anti-PD-L1 and Anti-CTLA-4 Immunotherapy by Modulating the Tumour Microenvironment in a 4T1 Orthotopic Mouse Model","first-page":"456","author":"Zhang","year":"2021"},{"key":"10.1016\/j.canlet.2022.215937_bib83","doi-asserted-by":"crossref","first-page":"E6157","DOI":"10.1073\/pnas.1700363114","article-title":"Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas","volume":"114","author":"Du","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2022.215937_bib84","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.215937_bib85","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128217","article-title":"Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma","volume":"4","author":"Wirsching","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2022.215937_bib86","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib87","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215937_bib88","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-18-3767","article-title":"PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma","volume":"25","author":"Smith","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib89","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/d41573-020-00204-y","article-title":"Combinations take centre stage in PD1\/PDL1 inhibitor clinical trials","volume":"20","author":"Upadhaya","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2022.215937_bib90","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.215937_bib91","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","article-title":"MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL)","volume":"32","author":"Ribas","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib92","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib93","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib94","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2017.35.15_suppl.9510","article-title":"Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma","volume":"35","author":"Andtbacka","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib95","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2017.35.15_suppl.3014","article-title":"Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy","volume":"35","author":"Curti","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib96","doi-asserted-by":"crossref","first-page":"VIII732","DOI":"10.1093\/annonc\/mdy424.050","article-title":"Phase Ib KEYNOTE-200: a study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients","volume":"29","author":"Rudin","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib97","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.215937_bib98","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib99","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib100","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2021.06.005","article-title":"Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody","volume":"518","author":"Tian","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2022.215937_bib102","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215937_bib103","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1","volume":"7","author":"Thomas","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.canlet.2022.215937_bib104","first-page":"A629","article-title":"594 BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment","volume":"8","author":"Semmrich","year":"2020","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.canlet.2022.215937_bib105","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1220467","article-title":"Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition","volume":"5","author":"Kleinpeter","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2022.215937_bib106","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","article-title":"Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy","volume":"77","author":"Bartee","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib107","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jamcollsurg.2019.12.027","article-title":"Novel chimeric immuno-oncolytic virus CF33-hNIS-antiPDL1 for the treatment of pancreatic cancer","volume":"230","author":"Woo","year":"2020","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.canlet.2022.215937_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.canlet.2022.215937_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215487","article-title":"Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: systematic review and meta-analytics","volume":"14","author":"Sukik","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2022.215937_bib110","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2022.215937_bib111","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.ymthe.2020.02.017","article-title":"Transient inhibition of PI3K\u03b4 enhances the therapeutic effect of intravenous delivery of oncolytic vaccinia virus","volume":"28","author":"Ferguson","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib112","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1128\/JVI.06860-11","article-title":"Integrin \u03b21 mediates vaccinia virus entry through activation of PI3K\/Akt signaling","volume":"86","author":"Izmailyan","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2022.215937_bib113","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/cells10050978","article-title":"Systemic delivery of oncolytic adenovirus to tumors using tumor-infiltrating lymphocytes as carriers","volume":"10","author":"Santos","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2022.215937_bib114","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.18632\/oncotarget.27845","article-title":"NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy","volume":"11","author":"Cornejo","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.215937_bib115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.omto.2021.03.013","article-title":"Efficient delivery of oncolytic enterovirus by carrier cell line NK-92","volume":"21","author":"Podshivalova","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2022.215937_bib116","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/gt.2008.45","article-title":"Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth","volume":"15","author":"Munguia","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib117","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jconrel.2015.07.019","article-title":"Cell membrane-camouflaged nanoparticles for drug delivery","volume":"220","author":"Luk","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2022.215937_bib118","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","article-title":"Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy","volume":"19","author":"Lv","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.canlet.2022.215937_bib119","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1038\/s41467-019-13744-8","article-title":"Artificially cloaked viral nanovaccine for cancer immunotherapy","volume":"10","author":"Fusciello","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215937_bib120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint Antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2022.215937_bib121","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib122","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1158\/1078-0432.CCR-21-0660","article-title":"Can biomarkers guide oncolytic virus immunotherapy?","volume":"27","author":"Kaufman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib123","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1158\/1078-0432.CCR-20-3365","article-title":"Mutations in the ifn\u03b3-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment","volume":"27","author":"Nguyen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib124","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS-STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2022.215937_bib125","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/JVI.05738-11","article-title":"Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion","volume":"86","author":"Jensen","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2022.215937_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.canlet.2022.215937_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137573","article-title":"Drug-Encoded biomarkers for monitoring biological therapies","volume":"10","author":"Tsoneva","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2022.215937_bib128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nbt.4327","article-title":"Checkpoint inhibitors go viral","volume":"37","author":"Senior","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2022.215937_bib129","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.989771","article-title":"Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy","volume":"4","author":"Liikanen","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2022.215937_bib130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2022.215937_bib131","article-title":"Optimal timing of PD-1 blockade in combination with oncolytic virus therapy","author":"Nguyen","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2022.215937_bib132","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1172\/JCI125039","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2022.215937_bib133","article-title":"Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy","volume":"2","author":"Belcaid","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.canlet.2022.215937_bib134","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1532763","article-title":"Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model","volume":"8","author":"Kuryk","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2022.215937_bib135","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41598-017-02503-8","article-title":"Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2022.215937_bib136","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cac2.12229","article-title":"The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation","volume":"41","author":"Ma","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2022.215937_bib137","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/cac2.12226","article-title":"Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates","volume":"41","author":"Shang","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2022.215937_bib138","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e21013","article-title":"OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment","volume":"35","author":"Cui","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib139","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-16-2900","article-title":"Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients","volume":"23","author":"Streby","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib140","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1517\/13543784.17.7.1105","article-title":"Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy","volume":"17","author":"Kelly","year":"2008","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.canlet.2022.215937_bib141","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients","volume":"30","author":"Garc\u00eda","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib142","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.canlet.2022.215937_bib143","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib144","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib145","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.2020.38.4_suppl.716","article-title":"A phase I\/II study combining a TMZ-CD40L\/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel\/gemcitabine chemotherapy in advanced pancreatic cancer: an interim report","volume":"38","author":"Musher","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib146","doi-asserted-by":"crossref","first-page":"v271","DOI":"10.1093\/annonc\/mdz247.037","article-title":"Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial","volume":"30","author":"Garcia-Carbonero","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib147","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2022.215937_bib148","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-4939-2727-2_19","article-title":"A phase 2, open-label, randomized study of pexa-vec (JX-594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma","volume":"1317","author":"Breitbach","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2022.215937_bib149","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215937_bib150","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib151","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/mt.2014.194","article-title":"First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity","volume":"23","author":"Zeh","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2022.215937_bib152","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215937_bib153","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215937_bib154","doi-asserted-by":"crossref","first-page":"v536","DOI":"10.1093\/annonc\/mdz255.007","article-title":"Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti\u2013PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)","volume":"30","author":"Rischin","year":"2019","journal-title":"Ann. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522004244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522004244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:08:05Z","timestamp":1759594085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522004244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":154,"alternative-id":["S0304383522004244"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215937","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"215937"}}